{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:25:25Z","timestamp":1747221925108,"version":"3.40.5"},"reference-count":28,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Objective: To evaluate the process of diagnosing patients with malignant pleural mesothelioma (MPM) at a tertiary care hospital. Methods: This was a retrospective study involving patients referred to a tertiary-care cancer center in Brazil between 2009 and 2020. The diagnostic process was divided into four steps: onset of symptoms, referral to a specialist visit, histopathological diagnosis, and beginning of treatment. The intervals between each phase and the factors for delays were evaluated. Data including clinical status, radiological examinations, staging, treatment modalities, and survival outcomes were collected. Results: During the study period, 66 patients (mean age = 64 years) were diagnosed with MPM and underwent treatment. Only 27 (41%) of the patients had knowledge of prior exposure to asbestos. The median number of months (IQR) between the onset of symptoms and the first specialist visit, between the specialist visit and histopathological characterization, and between definite diagnosis and beginning of treatment was, respectively, 6.5 (2.0-11.4), 1.5 (0.6-2.1), and 1.7 (1.2-3.4). The knowledge of prior asbestos exposure was associated with a shorter time to referral to a specialist (median: 214 vs. 120 days; p = 0.04). A substantial number of nondiagnostic procedures and false-negative biopsy results (the majority of which involved the use of Cope needle biopsy) were found to be decisive factors for the length of waiting time. The mean overall survival was 11.9 months. Conclusions: The unfamiliarity of health professionals with MPM and the patient's lack of knowledge of prior asbestos exposure were the major factors to cause a long time interval between the onset of symptoms and beginning of treatment. An overall survival shorter than 1 year is likely to have been due to the aforementioned delays.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20220064","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T17:13:13Z","timestamp":1663953193000},"page":"e20220064","source":"Crossref","is-referenced-by-count":3,"title":["Mesothelioma in a developing country: a retrospective analysis of the diagnostic process"],"prefix":"10.36416","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3834-5675","authenticated-orcid":false,"given":"Paulo","family":"Henrique Peitl Greg\u00f3rio1","sequence":"first","affiliation":[{"name":"1. Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, Sao Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8577-8708","authenticated-orcid":false,"given":"Ricardo","family":"Mingarini Terra2","sequence":"additional","affiliation":[{"name":"2. Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, Sao Paulo (SP) Brasil. Recebido: 16 fevereiro 2022."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9182-8126","authenticated-orcid":false,"given":"Leonardo","family":"Pontual Lima2","sequence":"additional","affiliation":[{"name":"2. Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, Sao Paulo (SP) Brasil. Recebido: 16 fevereiro 2022."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7243-5343","authenticated-orcid":false,"given":"Paulo","family":"Manuel P\u00eago-Fernandes1","sequence":"additional","affiliation":[{"name":"1. Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, Sao Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22288","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.            Park EK, Takahashi K, Hoshuyama T, Cheng TJ, Delgermaa V, Le GV, et al. Global magnitude of reported and unreported mesothelioma. Environ Health Perspect. 2011;119(4):514-518. https:\/\/doi.org\/10.1289\/ehp.1002845","DOI":"10.1289\/ehp.1002845"},{"key":"ref1","unstructured":"2.            The United States Geological Survey (USGS). National Minerals Information Center [homepage on the Internet]. USGS: Reston, VA, USA; [cited 2022 Jan 2]. Minerals Yearbook - 2015 [Adobe Acrobat document, 9 p.]. Available from: https:\/\/d9-wret.s3-us-west-2.amazonaws.com\/assets\/palladium\/production\/mineral-pubs\/asbestos\/myb1-2015-asbes.pdf"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.            Pedra F. Mortalidade por mesotelioma no Brasil de 1980 a 2010. [thesis] Rio de Janeiro: Escola Nacional de Sa\u00fade P\u00fablica Sergio Arouca; 2015. https:\/\/www.arca.fiocruz.br\/handle\/icict\/34320","DOI":"10.22239\/2317-269x.01881"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.            Ugolini D, Bonassi S, Cristaudo A, Leoncini G, Ratto GB, Neri M. Temporal trend, geographic distribution, and publication quality in asbestos research. Environ Sci Pollut Res Int. 2015;22(9):6957-6967. https:\/\/doi.org\/10.1007\/s11356-014-3925-1","DOI":"10.1007\/s11356-014-3925-1"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.            Algranti E, Ramos-Bonilla JP, Terracini B, Santana VS, Comba P, Pasetto R, et al. Prevention of Asbestos Exposure in Latin America within a Global Public Health Perspective. Ann Glob Health. 2019;85(1):49. https:\/\/doi.org\/10.5334\/aogh.2341","DOI":"10.5334\/aogh.2341"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.            Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655. https:\/\/doi.org\/10.1097\/00000421-198212000-00014","DOI":"10.1097\/00000421-198212000-00014"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.            Rojas L, Cardona AF, Trejo-Rosales R, Zatarain-Barr\u00f3n ZL, Ram\u00edrez-Tirado LA, Ruiz-Pati\u00f1o A, et al. Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP). Thorac Cancer. 2019;10(3):508-518. https:\/\/doi.org\/10.1111\/1759-7714.12967","DOI":"10.1111\/1759-7714.12967"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.            Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89(10):716-724C. https:\/\/doi.org\/10.2471\/BLT.11.086678","DOI":"10.2471\/blt.11.086678"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.            Brasil. Minist\u00e9rio da Sa\u00fade. Instituto Nacional do C\u00e2ncer (INCA). Observat\u00f3rio da Pol\u00edtica Nacional de Controle do Tabaco; c2021 [homepage on the Internet]. Rio de Janeiro: INCA; [updated 2022 May 13; cited 2021 Oct 2]. Dados e n\u00fameros da preval\u00eancia do tabagismo; [about 32 screens]. Available from: https:\/\/www.inca.gov.br\/observatorio-da-politica-nacional-de-controle-do-tabaco\/dados-e-numeros-prevalencia-tabagismo","DOI":"10.26420\/annalsthyroidres.2021.1083"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.          Algranti E. Tabagismo e ocupa\u00e7\u00e3o: elo de exposi\u00e7\u00f5es pouco explorado como estrat\u00e9gia de combate ao tabagismo. J Pneumologia. 2001;27(4):07. https:\/\/doi.org\/10.1590\/S0102-35862001000400001 https:\/\/doi.org\/10.1590\/S0102-35862001000400001","DOI":"10.1590\/s0102-35862001000400001"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.          Osinubi OY, Afilaka AA, Doucette J, Golden A, Soriano T, Rovner E, et al. Study of smoking behavior in asbestos workers. Am J Ind Med. 2002;41(1):62-69. https:\/\/doi.org\/10.1002\/ajim.10031","DOI":"10.1002\/ajim.10031"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.          Malta DC, Flor LS, Machado \u00cdE, Felisbino-Mendes MS, Brant LCC, Ribeiro ALP, et al. Trends in prevalence and mortality burden attributable to smoking, Brazil and federated units, 1990 and 2017. Popul Health Metr. 2020;18(Suppl 1):24. https:\/\/doi.org\/10.1186\/s12963-020-00215-2","DOI":"10.1186\/s12963-020-00215-2"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.          Landrigan PJ, Baker DB. The recognition and control of occupational disease. JAMA. 1991;266(5):676-680. https:\/\/doi.org\/10.1001\/jama.1991.03470050076026","DOI":"10.1097\/01206501-199203000-00019"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.          McDonald JC, McDonald AD. The epidemiology of mesothelioma in historical context. Eur Respir J. 1996;9(9):1932-1942. https:\/\/doi.org\/10.1183\/09031936.96.09091932","DOI":"10.1183\/09031936.96.09091932"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.          Fels Elliott DR, Jones KD. Diagnosis of Mesothelioma. Surg Pathol Clin. 2020;13(1):73-89. https:\/\/doi.org\/10.1016\/j.path.2019.10.001","DOI":"10.1016\/j.path.2019.10.001"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.          Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis. Cancer. 1993;72(2):389-393. https:\/\/doi.org\/10.1002\/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V","DOI":"10.1002\/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17.          Maskell NA, Gleeson FV, Davies RJ. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet. 2003;361(9366):1326-1330. https:\/\/doi.org\/10.1016\/S0140-6736(03)13079-6","DOI":"10.1016\/s0140-6736(03)13079-6"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.          Brasil. Minist\u00e9rio da Sa\u00fade. Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS. Diretrizes Brasileiras para Diagn\u00f3stico do Mesotelioma Maligno de Pleura; Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2020.","DOI":"10.11606\/t.5.2019.tde-17042019-092843"},{"key":"ref18","unstructured":"19.          Antman K, Hassan R, Eisner M, Ries LA, Edwards BK. Update on malignant mesothelioma. Oncology (Williston Park). 2005;19(10):1301-1316."},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.          Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7(11):1631-1639. https:\/\/doi.org\/10.1097\/JTO.0b013e31826915f1","DOI":"10.1097\/jto.0b013e31826915f1"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.          Meyerhoff RR, Yang CF, Speicher PJ, Gulack BC, Hartwig MG, D\u2019Amico TA, et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015;196(1):23-32. https:\/\/doi.org\/10.1016\/j.jss.2015.01.043","DOI":"10.1016\/j.jss.2015.01.043"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.          Basu S, Saboury B, Torigian DA, Alavi A. Current evidence base of FDG-PET\/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment. Mol Imaging Biol. 2011;13(5):801-811. https:\/\/doi.org\/10.1007\/s11307-010-0426-6","DOI":"10.1007\/s11307-010-0426-6"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.          Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763-772. https:\/\/doi.org\/10.1016\/S1470-2045(11)70149-8","DOI":"10.1016\/s1470-2045(11)70149-8"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24.          Taioli E, Wolf AS, Camacho-Rivera M, Kaufman A, Lee DS, Nicastri D, et al. Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients. PLoS One. 2015;10(12):e0145039. https:\/\/doi.org\/10.1371\/journal.pone.0145039","DOI":"10.1371\/journal.pone.0145039"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25.          Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2022;33(2):129-142. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.005","DOI":"10.1016\/j.annonc.2021.11.005"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.          Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial [published correction appears in Lancet. 2021 Feb 20;397(10275):670]. Lancet. 2021;397(10272):375-386. https:\/\/doi.org\/10.1016\/S0140-6736(20)32714-8","DOI":"10.1016\/s0140-6736(20)32714-8"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27.          Terra RM, Teixeira LR, Beyruti R, Takagaki TY, Vargas FS, Jatene FB. Malignant pleural mesothelioma: multidisciplinary experience in a public tertiary hospital [Article in Portuguese]. J Bras Pneumol. 2008;34(1):13-20. https:\/\/doi.org\/10.1590\/S1806-37132008000100004","DOI":"10.1590\/s1806-37132008000100004"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28.          Algranti E, Saito CA, Carneiro AP, Moreira B, Mendon\u00e7a EM, Bussacos MA. The next mesothelioma wave: mortality trends and forecast to 2030 in Brazil. Cancer Epidemi-ol. 2015;39(5):687-692. https:\/\/doi.org\/10.1016\/j.canep.2015.08.007","DOI":"10.1016\/j.canep.2015.08.007"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T17:13:59Z","timestamp":1663953239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jornaldepneumologia.com.br\/details\/3715\/en-US\/mesothelioma-in-a-developing-country--a-retrospective-analysis-of-the-diagnostic-process"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":28,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20220064","relation":{},"ISSN":["1806-3756"],"issn-type":[{"type":"electronic","value":"1806-3756"}],"subject":[],"published":{"date-parts":[[2022,9,23]]}}}